Skip to main content
Clinical Trials/JPRN-jRCT1062220115
JPRN-jRCT1062220115
Recruiting
Phase 3

Randomised clinical trial to investigate the Efficacy of CPAP for Mild cognitive Impairment with Obstructive Sleep Apnoea - MORE

Fujii Masanori0 sites130 target enrollmentMarch 31, 2023

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Fujii Masanori
Enrollment
130
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 31, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Fujii Masanori

Eligibility Criteria

Inclusion Criteria

  • 1\) Aged 50 years and over
  • 2\) AHI over 20 on polysomnography or AHI over 40 on brief monitoring with a confirmed diagnosis of OSAS
  • 3\) Patients with a clinical diagnosis of MCI based on DSM\-5 (Diagnostic \& Statistical Manual of Mental Disorders,5th edition) or NIA\-AA (National Institute on Aging\-Alzheimer Association Joint Working Group) diagnostic criteria.
  • 4\) Cases in which the attending physician is able to judge that CPAP treatment is possible, and cases in which the patient lives with or has a family member who can support the patient as a study partner throughout the course of treatment (at least 3 times a week face to face or telephone contact is possible).
  • 5\) After receiving a full explanation of the study, select patients who have been fully informed about their participation in the study, and who have given their written consent, either by themselves or by a proxy, with full understanding.

Exclusion Criteria

  • 1\) A respiratory event index of 60 or more on an out of center sleep testing or an apnoea\-hypopnoea index of 60 or more on a Polysomnography
  • 2\) Psychiatric disorders such as depression and schizophrenia
  • 3\) Delirium
  • 4\) Parkinson's disease
  • 5\) Medical conditions affecting cognitive function (hypothyroidism, parathyroid disorders, vitamin B12 and folic acid deficiency, neurosyphilis, neuro\-Beichet's disease and other collagen diseases, severe diabetes, chronic liver disorders, chronic respiratory diseases, hypoglycaemia, etc.)
  • 6\) Epilepsy
  • 7\) Neurosurgical diseases (e.g. brain tumours, chronic subdural haematomas, normal hydrocephalus) and massive stroke cases
  • 8\) Cases of new prescriptions or volume changes of dementia drugs in the last 3 months
  • 9\) Cases with a history of excessive alcohol consumption or alcohol dependence
  • 10\) Patients with severe visual or hearing impairment that interferes with daily life.

Outcomes

Primary Outcomes

Not specified

Similar Trials